GlobeImmune Signs R&D Agreement With NCI
GlobeImmune has signed a cooperative R&D agreement with the National Cancer Institute at the National Institutes of Health to jointly develop products intended to treat a variety of cancers.
GlobeImmune will utilize its proprietary Tarmogen technology to develop multiple immunotherapy products expressing various cancer antigens provided by the National Institutes of Health (NIH) and the NIH will conduct and fund preclinical and early clinical development of the product candidates.
Jeffrey Schlom, chief of the laboratory of tumor immunology and biology at the National Cancer Institute (NCI), will be the principal investigator for these studies.
Timothy Rodell, CEO of GlobeImmune, said: “We are delighted to be working with Dr Schlom and his colleagues at the National Cancer Institute. Their involvement will bring substantial expertise and resources to investigate the potential of our technologies with these important cancer targets. This collaboration has the potential to allow GlobeImmune to bring additional products into the clinic.”